LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects.

The LL genotype among subjects with paraoxonase (PON) polymorphism Met-Leu 54 has been shown to be associated with elevated risk of coronary heart disease. Indeed, insulin resistance (IR) is a well known cardiovascular risk factor that is likely attributable to a genetic background, lifestyle, and environmental factors such oxidative stress. Because subjects sharing the LL genotype have a more elevated degree of oxidative stress, one cannot rule out that in those subjects a more severe degree of IR can occur. Thus, the possible relationship between PON gene polymorphism and degree of IR was investigated. In 213 healthy subjects, the degree of IR was assessed by the homeostasis model assessment, and the Met-Leu 54 PON polymorphism was detected. The frequency was 0.366 for the LL genotype, 0.469 for the LM genotype, and 0.164 for the MM genotype. Comparing the three genotype groups, LL genotype had the more severe degree of IR, compared with LM (P < 0.01) and MM (P < 0.01) genotypes. No difference between LM and MM genotypes was found (P = 0.49). Subjects carrying the LL genotype were associated with the IR syndrome picture more than individuals carrying the M allele because they were more overweight and had the highest levels of triglycerides and blood pressure and the lowest values of plasma high-density lipoprotein cholesterol. In a multivariate stepwise regression analysis, LL genotype was a significant predictor of IR, independent of age, sex, body mass index, fasting plasma triglycerides, and high-density lipoprotein cholesterol (P < 0.001). In conclusion, the presence of LL PON genotype is associated with a more severe degree of IR. Thus, IR might be the possible missing link between Met-Leu 54 PON polymorphism and the increased cardiovascular risk.

[1]  G. Paolisso,et al.  Oxidative stress and insulin action: is there a relationship? , 1996, Diabetologia.

[2]  G. Schellenberg,et al.  Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[3]  A. Gardemann,et al.  The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. , 2000, Atherosclerosis.

[4]  E. Anggard,et al.  Antioxidants, diabetes and endothelial dysfunction. , 2000, Cardiovascular research.

[5]  Y. Yazaki,et al.  Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. , 2000, Atherosclerosis.

[6]  J. Ferrières,et al.  Paraoxonase activity in two healthy populations with differing rates of coronary heart disease , 2000, European journal of clinical investigation.

[7]  G. Schellenberg,et al.  Paraoxonase ( PON 1 ) Phenotype Is a Better Predictor of Vascular Disease Than Is PON 1 192 or PON 1 55 Genotype , 2000 .

[8]  A. Gardemann,et al.  The paraoxonase Leu – Met 54 and Gln – Arg 191 gene polymorphisms are not associated with the risk of coronary heart disease , 2000 .

[9]  E. Bonora,et al.  Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. , 2000, Diabetes care.

[10]  Paolisso,et al.  Advancing age and insulin resistance: new facts about an ancient history , 1999, European journal of clinical investigation.

[11]  T. Lehtimäki,et al.  Association between M/L55-polymorphism of paraoxonase enzyme and oxidative DNA damage in patients with type 2 diabetes mellitus and in control subjects , 1999, Human Genetics.

[12]  A. Rudich,et al.  Lipoic acid protects against oxidative stress induced impairment in insulin stimulation of protein kinase B and glucose transport in 3T3-L1 adipocytes , 1999, Diabetologia.

[13]  A. Rudich,et al.  Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. , 1998, Diabetes.

[14]  T. Dantoine,et al.  Paraoxonase as a Risk Marker for Cardiovascular Disease: Facts and Hypotheses , 1998, Clinical chemistry and laboratory medicine.

[15]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[16]  D. Sanghera,et al.  DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. , 1998, American journal of human genetics.

[17]  A. Lusis,et al.  Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? , 1998, American journal of human genetics.

[18]  R. James,et al.  Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[19]  A. Rudich,et al.  Lipoic acid reduces glycemia and increases muscle GLUT4 content in streptozotocin-diabetic rats. , 1997, Metabolism: clinical and experimental.

[20]  P. Froguel,et al.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. , 1997, The Journal of clinical investigation.

[21]  M. Jauhiainen,et al.  The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. , 1996, The Journal of clinical investigation.

[22]  D. Moller,et al.  Candidate Genes for Insulin Resistance , 1996, Diabetes Care.

[23]  M. Laakso,et al.  Hyperinsulinemia predicts multiple atherogenic changes in lipoproteins in elderly subjects. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[24]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.

[25]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[26]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[27]  J. Ziegenhorn,et al.  Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. , 1983, Clinical chemistry.

[28]  E. Voutilainen,et al.  Comparison of different analytical and precipitation methods for direct estimation of serum high-density lipoprotein cholesterol. , 1981, Scandinavian journal of clinical and laboratory investigation.

[29]  A. Wahlefeld Triglycerides Determination after Enzymatic Hydrolysis , 1974 .